Differential expression of MMP-2, MMP-9 and TIMP proteins in thoracic aortic aneurysm–comparison with and without bicuspid aortic valve: A meta-analysis;Differentielle Expression von MMP-2, MMP-9 und TIMP-Pro-teine beim thorakalen Aortenaneurysma - Vergleich mit und ohne bikuspider Aortenklappe: Eine systematische Meta -Analyse

Vasa - European Journal of Vascular Medicine

Volumn 43, Issue 6, 2014, Pages 433-442

  Rabkin, Simon W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Matrix metalloproteinase; Meta analysis; Thoracic aortic aneurysm. bicuspid aortic valve; Tissue inhibitors of metalloproteinase

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; ASCENDING AORTA; BICUSPID AORTIC VALVE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; THORACIC AORTA ANEURYSM;

EID: 84924722084     PISSN: 03011526     EISSN: 16642872     Source Type: Journal    
DOI: 10.1024/0301-1526/a000390     Document Type: Article

References (37)

1. Olsson C, Thelin S, Stahle E, Ekbom A, Granath F. Thoracic aortic an-eurysm and dissection: increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 cases from 1987 to 2002. Circulation. 2006; 114: 2611–2618.
2. Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, Elefteriades JA. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg. 2002; 73: 17–27.
3. Schlatmann TJ, Becker AE. Patho-genesis of dissecting aneurysm of aorta. Comparative histopatholog-ic study of significance of medial changes. Am J Cardiol. 1977; 39: 21–26.
4. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; 69: 562–573.
5. Galis ZS, Khatri JJ. Matrix metal-loproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002; 90: 251–262.
6. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 2010; 1803: 55–71.
7. Bode W, Fernandez-Catalan C, Tschesche H, Grams F, Nagase H, Maskos K. Structural properties of matrix metalloproteinases. Cell Mol Life Sci. 1999; 55: 639–652.
8. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol. 2008; 40: 1362–1378.
9. Vandooren J, Van den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Bio-chem Mol Biol. 2013; 48: 222–272.
10. Geng L, Wang W, Chen Y, Cao J, Lu L, Chen Q, He R, Shen W. Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-in-duced thoracic aortic aneurysm in a rat model. Exp Mol Pathol. 2010; 89: 72–81.
11. Yang HH, Kim JM, Chum E, van Breemen C, Chung AW. Effective-ness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome. J Thorac Cardiovasc Surg. 2010; 140: 305–312.e2.
12. Tadros TM, Klein MD, Shapira OM. Ascending aortic dilatation associated with bicuspid aortic valve. Pathophysiology, molecular biology, and clinical implications. Circulation. 2009; 119: 880–890.
13. Evangelista A. Bicuspid aortic valve and aortic root disease. Curr Car-diol Rep. 2011; 13: 234–241.
14. Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Car-diol. 2010; 55: 2789–2800.
15. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey Jr DE, Eagle KA, Hermann LK, Is-selbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW, Mile-wicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM, American College of Cardiology F, American Heart Association Task Force on Practice G, American Association for Thoracic S, American College of R, American Stroke A, Society of Cardiovascular A, Society for Cardiovascular Angiography and I, Society of Interventional R, Society of Thoracic S, Society for Vascular M. 2010 ACCF/AHA/ AATS/ACR/ASA/SCA/SCAI/SIR/ STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary. A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Pra. Catheter Cardiovasc Interv. 2010; 76: E43–86.
16. Chan KK, Rabkin SW. Increasing Prevalence of Hypertension Among Patients With Thoracic Aorta Dissection: Trends Over Eight De-cades--A Structured Meta-analysis. Am J Hypertens. 2014; 27: 907–917.
17. Moher D, Liberati A, Tetzlaf J, Alt-man DG, PRISMA G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62: 1006–1012.
18. Boyum J, Fellinger EK, Schmoker JD, Trombley L, McPartland K, Ittleman FP, Howard AB. Matrix metalloproteinase activity in thoracic aortic aneurysms associated with bicuspid and tricuspid aortic valves. J Thorac Cardiovasc Surg. 2004; 127: 686–691.
19. Schmoker JD, McPartland KJ, Fell-inger EK, Boyum J, Trombley L, Ittleman F P, Terrien 3rd C, Stanley A, Howard A. Matrix metal-loproteinase and tissue inhibitor expression in atherosclerotic and nonatherosclerotic thoracic aortic aneurysms. J Thorac Cardiovasc Surg. 2007; 133: 155–161.
20. Fedak PW, de Sa MP, Verma S, Nili N, Kazemian P, Butany J, Strauss BH, Weisel RD, David TE. Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. J Thorac Cardiovasc Surg. 2003; 126: 797–806.
21. Ikonomidis JS, Ruddy JM, Benton Jr SM, Arroyo J, Brinsa TA, Stroud RE, Zeeshan A, Bavaria JE, Gorman 3rd JH, Gorman RC, Spinale FG, Jones JA. Aortic dilatation with bicuspid aortic valves: cusp fusion correlates to matrix metalloproteinases and inhibitors. Ann Thorac Surg. 2012; 93: 457–463.
22. Koullias GJ, Ravichandran P, Korkolis DP, Rimm DL, Elefteria-des JA. Increased tissue microarray matrix metalloproteinase expression favors proteolysis in thoracic aortic aneurysms and dissec-tions. Ann Thorac Surg. 2004; 78: 2106–2110.
23. LeMaire SA, Wang X, Wilks JA, Carter SA, Wen S, Won T, Leon-ardelli D, Anand G, Conklin LD, Wang XL, Thompson RW, Coselli JS. Matrix metalloproteinases in ascending aortic aneurysms: bicuspid versus trileaflet aortic valves. J Surg Res. 2005; 123: 40–48.
24. Mi T, Nie B, Zhang C, Zhou H. The elevated expression of osteo-pontin and NF-kB in human aortic aneurysms and its implication. J Huazhong Univ Sci Technol Sci. 2011; 31: 602–607.
25. Mohamed SA, Noack F, Schoell-ermann K, Karluss A, Radtke A, Schult-Badusche D, Radke P W, Wenzel BE, Sievers HH. Elevation of matrix metalloproteinases in different areas of ascending aortic aneurysms in patients with bicuspid and tricuspid aortic valves. Sci World J. 2012; 2012.
26. Lesauskaite V, Epistolato MC, Cast-agnini M, Urbonavicius S, Tangan-elli P. Expression of matrix metallo-proteinases, their tissue inhibitors, and osteopontin in the wall of thoracic and abdominal aortas with dilatative pathology. Hum Pathol. 2006; 37: 1076–1084.
27. Ruddy JM, Jones JA, Stroud RE, Mukherjee R, Spinale FG, Ikono-midis JS. Differential effect of wall tension on matrix metalloprotein-ase promoter activation in the thoracic aorta. J Surg Res. 2010; 160: 333–339.
28. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson U P. Tissue inhibi-tors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997; 74: 111–122.
29. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006; 25: 99–113.
30. Ejiri J, Inoue N, Tsukube T, Mune-zane T, Hino Y, Kobayashi S, Hirata K, Kawashima S, Imajoh-Ohmi S, Hayashi Y, Yokozaki H, Okita Y, Yokoyama M. Oxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of station and angiotensin II type 1 receptor blocker. Cardiovasc Res. 2003; 59: 988–996.
31. Rabkin S, Janusz M. Aortic Wall Stress in Hypertension and Ascending Thoracic Aortic Aneurysms: Implications for Antihypertensive Therapy. High Blood Press Cardio-vasc Prev. DOI 10.100.
32. Jones JA, Stroud RE, O’Quinn EC, Black LE, Barth JL, Elefteria-des JA, Bavaria JE, Gorman 3rd JH, Gorman RC, Spinale FG, Ikono-midis JS. Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction. Circ Genet. 2011; 4: 605–613.
33. Peng S, Larsson A, Wassberg E, Ger-wins P, Thelin S, Fu X, Westermark P. Role of aggregated medin in the pathogenesis of thoracic aortic an-eurysm and dissection. Lab Inves-tig. 2007; 87: 1195–1205.
34. Lyman GH, Kuderer NM. The strengths and limitations of meta-analyses based on aggregate data. BMC Med Res Methodol. 2005; 5: 14.
35. Wilton E, Bland M, Thompson M, Jahangiri M. Work in progress report - Valves: Matrix metallopro-teinase expression in the ascending aorta and aortic valve. Interact Cardiovasc Thorac Surg. 2008; 7: 37–40.
36. Taketani T, Imai Y, Morota T, Maemura K, Morita H, Haya-shi D, Yamazaki T, Nagai R, Takamoto S. Altered patterns of gene expression specific to thoracic aortic aneurysms: microar-ray analysis of surgically resected specimens. Int Heart J. 2005; 46: 265–277.
37. Phillippi JA, Klyachko EA, Kenny 4th JP, Eskay MA, Gorman RC, Gleason TG. Basal and oxi-dative stress-induced expression of metallothionein is decreased in ascending aortic aneu-rysms of bicuspid aortic valve patients. Circulation. 2009; 119: 2498–2506.